Search

Displaying results 6441 - 6450 of 8194 in total
  1. Drug

    Palm oil

    go.drugbank.com/drugs/DB14377
    Investigational

    It is not an approved drug.

  2. Drug

    ISIS 104838

    go.drugbank.com/drugs/DB16201
    Investigational

    ISIS 104838 is under investigation in clinical trial NCT00048321 (ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis).

  3. Drug

    PRX-OTC

    go.drugbank.com/drugs/DB17680
    Experimental

    PRX-OTC is an intracellular enzyme replacement therapy designed to replace missing or defective enzyme in patients with ornithine transcarbamylase deficiency.

  4. Drug

    SPL23-2

    go.drugbank.com/drugs/DB17866
    Experimental

    SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.[L46767]

  5. Drug

    TTX-MC138

    go.drugbank.com/drugs/DB18628
    Investigational

    TTX-MC138 is an antisense oligonucleotide targeting miR-10b.[L48335] It is under investigation for the treatment of various metastatic cancers.

  6. Drug

    QRX-411

    go.drugbank.com/drugs/DB17868
    Experimental

    It addresses the underlying cause of Usher syndrome due to the c.7595-2144A>G mutation in the _USH2A_ gene.[L46777]

  7. Drug

    Fleroxacin

    go.drugbank.com/drugs/DB04576
    Experimental

    Fleroxacin is not an inhibitor of CYP1A2.[A39048]

  8. Drug

    Dihydroxyacetone phosphate

    go.drugbank.com/drugs/DB04326
    Investigational

    Dihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.

  9. Drug

    ATX-F8-117

    go.drugbank.com/drugs/DB17712
    Experimental

    ATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]

  10. Drug

    BHV-5000

    go.drugbank.com/drugs/DB17817
    Experimental

    BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]